IN VITRO ANALYSIS OF NOVEL ANTI-CD20 ANTIBODY GA101 AND RITUXIMAB IN MANTLE CELL LYMPHOMA

被引：0
|
作者：
Heinrich, D. [1 ]
Decheva, K. [1 ]
Weinkauf, M. [1 ]
Hutter, G. [1 ]
Zimmermann, Y. [1 ]
Weiglein, T. [1 ]
Hiddemann, W. [1 ]
Dreyling, M. [1 ]
机构：
[1] Univ Hosp Munich, Dept Med 2, Munich, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0183
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [1] Differential Regulation Patterns of Anti-CD20 Antibodies GA101 and Rituximab in Mantle Cell Lymphoma
    Heinrich, Daniel
    Weinkauf, Marc
    Hutter, Grit
    Decheva, Kristina
    Zimmermann, Yvonne
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    [J]. BLOOD, 2010, 116 (21) : 767 - 768
  • [2] Anti-CD20 Antibody GA101 Shows Higher Cytotoxicity but Is Competitively Displaced by Rituximab in Mantle Cell Lymphoma.
    Heinrich, Daniel A.
    Klein, Christian
    Decheva, Kristina
    Weinkauf, Marc
    Hutter, Grit
    Zimmermann, Yvonne
    Weiglein, Tobias
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    [J]. BLOOD, 2009, 114 (22) : 1059 - 1059
  • [3] GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
    Waseem Bakkour
    Ian H. Coulson
    [J]. Dermatology and Therapy, 2012, 2 (1)
  • [4] GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
    Bakkour, Waseem
    Coulson, Ian H.
    [J]. DERMATOLOGY AND THERAPY, 2012, 2 (01)
  • [5] Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
    Dalle, Stephane
    Reslan, Lina
    de Horts, Timothee Besseyre
    Herveau, Stephanie
    Herting, Frank
    Plesa, Adriana
    Friess, Thomas
    Umana, Pablo
    Klein, Christian
    Dumontet, Charles
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (01) : 178 - 185
  • [6] Obinutuzumab (GA101) - a different anti-CD20 antibody with great expectations
    Illidge, Tim M.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 543 - 545
  • [7] 2D-PAGE-based proteomics identifies differential protein patterns in mantle cell lymphoma after anti-CD20 antibody treatment (GA101 or Rituximab)
    Weinkauf, M.
    Heinrich, D.
    Hiddemann, W.
    Dreyling, M.
    [J]. ONKOLOGIE, 2010, 33 : 46 - 46
  • [8] Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
    Patz, Michaela
    Isaeva, Polina
    Forcob, Nche
    Mueller, Bianka
    Frenzel, Lukas P.
    Wendtner, Clemens-Martin
    Klein, Christian
    Umana, Pablo
    Hallek, Michael
    Krause, Guenter
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (03) : 295 - 306
  • [9] Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way
    Niederfellner, Gerhard J.
    Lammens, Alfred
    Schwaiger, Manfred
    Georges, Guy
    Wiechmann, Kornelius
    Franke, Andreas
    Schaefer, Wolfgang
    Jenewein, Stefan
    Slootstra, Jerry
    Moessner, Ekkehard
    Umana, Pablo
    Hopfner, Karl-Peter
    Klein, Christian
    [J]. BLOOD, 2009, 114 (22) : 1435 - 1435
  • [10] In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL
    Zenz, Thorsten
    Volden, Matthias
    Mast, Theresa
    Sarno, Antonio
    Winkler, Dirk
    Schnaiter, Andrea
    Buehler, Andreas
    Klein, Christian
    Umana, Pablo
    Doehner, Hartmut
    Stilgenbauer, Stephan
    [J]. BLOOD, 2009, 114 (22) : 939 - 940
12345